IN THE CLAIMS

1. (Original) A compound of formula:

I,

wherein

R¹ is selected from the group

-H,

-COR⁴, and

-COOCHR⁵OCOR⁴;

R² and R³ are independently selected from

-H, and

-OR⁵;

R⁴ is selected from the group

- -C₁₋₆ alkyl,
- -lower alkyl substituted by up to 4 groups independently selected from
- -NR⁵R⁶,
- -SR⁵,
- -OR⁵,

-aryl,

- -aryl substituted by up to 2 groups independently selected from
- -OR5 and C1-4 lower alkyl, and
- -heteroaryl, and
- -heterocycle;

R⁵ and R⁶ are independently selected from

- -H, and
- C₁₋₅ lower alkyl,

or, alternatively, -NR⁵R⁶ can form a ring having 3 to 7 atoms, said ring optionally including one or more additional N or O atoms.

- 2. (Original) The compound of claim 1 wherein R¹ is -COR⁴.
- 3. (Original) The compound of claim 2 wherein R² is H.
- 4. (Original) The compound of claim 3 wherein R³ is H.
- 5. (Currently Amended) The compound of claim 4 which is selected from the group:

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]- N-phenylacetamide (Ex. 2);

N-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylpropanamide (Ex. 3);

2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide acetic acid salt (Ex. 6b);

- 2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylacetamide hydrochloric acid salt (Ex. 6c);
- (2S)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide (Ex. 7b);
- (2S)-2-amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide acetic acid salt (Ex. 7c);
- (2S)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide hydrochloric acid salt (Ex. 7d);
- (2S)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-3-phenyl-*N*-phenylpropanamide (Ex. 8b);
- (2S)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-3-phenyl-*N*-phenylpropanamide hydrochloric acid salt (Ex. 8c);
- (2S)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methyl-*N*-phenylpentanamide acetic acid salt (Ex. 9b);
- (2S)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methyl-*N*-phenylpentanamide hydrochloric acid salt (Ex. 9e);
- (2*S*)-2-Amino-3-(4-hydroxyphenyl)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylpropanamide hydrochloric acid salt (Ex. 10b);

(2S)-2,6-Diamino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylhexanamide di-hydrochloric acid salt (Ex. 11b);

(2*S*)-2-Amino-3-indol-3-yl-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylpropanamide hydrochloric acid salt (Ex. 12b);

(2S)-2-Amino-3-hydroxy-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-phenylpropanamide (Ex. 13b);

(2*R*)-2-Amino-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-4-methylthio-*N*-phenylbutanamide hydrochloric acid <u>salt</u> saltn (Ex. 14b);

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylpentanamide (Ex. 16); and

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylbutanamide (Ex. 17).

6. (Currently Amended) The compound of claim 2 which is selected from the group:

N-(4-Hydroxyphenyl)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]acetamide (Ex. 19e); and

N-(4-methoxyphenyl)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]acetamide (Ex. 21).

7. (Original) The compound of claim 1 wherein R¹ is -COOCHR⁵OCOR⁴.

- 8. (Original) The compound of claim 7 wherein R² is H.
- 9. (Original) The compound of claim 8 wherein R³ is H.
- 10. (Currently Amended) The compound of claim 9 which is selected from the group:

 $\{N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylcarbamoyloxy\}methyl acetate (Ex. 4b);$

 $\{N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-N-phenylcarbamoyloxy\}methyl 2-(dimethylamino)acetate (Ex. 5a);$

{*N*-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]- *N*-phenylcarbamoyloxy}methyl 2-(dimethylamino)acetate hydrochloric acid salt (Ex. 5b); and

{*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]- *N*-phenylcarbamoyloxy}methyl piperidine-4-carboxylate trifluoroacetic acid salt (Ex. 15).

- 11. (Original) The compound of claim 1 wherein R¹ is H.
- 12. (Original) The compound of claim 11 wherein R² is H.
- 13. (Currently Amended) The compound of claim 12 which is selected from the group:

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one (Ex. 1g);

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one methanesulfonate salt (Ex. 1h);

7-[(4-Hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one (Ex. 18); and

3-(4-Methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one.

14. (Original) A compound selected from the group:

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one,

3-(4-Methoxyphenyl)-1-phenyl-7-(phenylamino)-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one methanesulfonate salt,

7-[(4-Hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one, and

3-(4-Methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one.

15. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and pharmaceutically acceptable carrier or excipient.

Claim 16. (Canceled).

Claim 17. (Canceled).

- 18. (Currently Amended) The A method of claim 16 wherein the cancer is treating lung, colon or prostate cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 19. (Currently Amended) The A method of claim 17 wherein the cancer is controlling lung, colon or prostate cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1.
 - 20. (Currently Amended) A compound selected from the group:

(Chloromethoxy)-*N*-[3-(4-methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]-*N*-benzamide [Example 4a]

3-(4-Methoxyphenyl)-1-phenyl-7-{[4-(1,1,2,2-tetramethyl-1-silapropoxy) phenyl]amino}-1,3,4-trihydropyrimidino[4,5-d]pyrimidin-2-one [Example 19c], and

N-[3-(4-Methoxyphenyl)-2-oxo-1-phenyl(1,3,4-trihydropyrimidino[4,5-d]pyrimidin-7-yl)]- N-[4-(1,1,2,2-tetramethyl-1-silapropoxy)phenyl]acetamide [Example 19d].